Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD), a clinical-stage gene therapy company for inherited retinal diseases, will join the Russell 3000®, Russell 2000® and Russell Microcap® Indexes when the U.S. market opens on June 29, 2026, following the June 2026 Russell indexes reconstitution.
Membership is based on market-capitalization rankings determined by FTSE Russell and lasts until the next semi-annual reconstitution. Russell US indexes are widely used as benchmarks, with about $12.2 trillion in assets benchmarked to them as of June 2025.
Positive
- Added to Russell 3000®, Russell 2000® and Russell Microcap® indexes effective June 29, 2026
- Exposure to Russell US indexes that had about $12.2 billion benchmarked assets as of June 2025
Negative
- None.
News Market Reaction – IRD
In the Jun 26 session, IRD gained 7.53%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.7% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Pipeline update | Positive | +4.1% | Outlined progress and timelines across five IRD gene therapy programs and cash runway. |
| Jun 02 | R&D event | Neutral | -3.2% | Announced plans to host a virtual R&D Science Forum on IRD pipeline programs. |
| May 28 | Equity inducements | Neutral | +3.8% | Reported stock option inducement grants for new non-executive employees under 2021 plan. |
| May 27 | Conference presentation | Neutral | +1.2% | Scheduled presentation at the 2026 Jefferies Global Healthcare Conference with webcast access. |
| May 13 | Conference presentation | Neutral | -2.9% | Announced presentation at the RBC Capital Markets 2026 Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed, mostly moderate price reactions, with both aligned and divergent moves relative to event tone.
Key Terms
russell 3000 financial
russell 2000 financial
russell microcap financial
ftse russell financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000®, the Russell 2000® and the Russell Microcap® Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution.
“We are pleased to be included in these Russell indexes, which provide validation of the progress we’re making in advancing our gene therapies for inherited retinal diseases,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “We welcome the enhanced visibility within the investment community as we continue on our strategic path.”
The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, approximately
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward-Looking Statements
This press release contains certain statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to our inclusion in the Russell indexes and related benefits, the clinical development, clinical results, preclinical data and future plans for OPGx-LCA5, OPGx-BEST1, OPGx-MERTK, OPGx-RDH12, OPGx-RHO and earlier stage programs, and expectations regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to publicly update any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
